We Give Shareholders a Voice
Levi & Korsinsky, LLP announces the commencement of a class action lawsuit in the United States District Court for the District of Nevada on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) who purchased shares between December 16, 2015 and September 16, 2016.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the “FDA”) questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants’ public statements concerning the Company’s business, operations and prospects were materially false and misleading at all relevant times. If you suffered a loss in Spectrum Pharmaceuticals, you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.